In Europe, there are more clinical trials conducted in oncology than in any other therapeutic area; oncology trials account for approximately 35% of all clinical trials in Europe. As a result, EastHORN has more experience in oncology than in any other therapeutic area.
The indications that EastHORN has been engaged in are:
- Anaemia – Chemotherapy Induced
- B-CLL
- Breast Cancer
- Cervical Cancer
- Chemotherapy Induced Neutropenia
- Chemotherapy Induced Anemia
- Colorectal Cancer
- Gallbladder Cancer
- Gastric Cancer
- gCSF in Bone Marrow Transplantation
- GI Stromal Tumor
- Glioblastoma
- Head and Neck Cancer
- Hepatocelullar Carcinoma
- High-grade Glioma
- Leukemia
- Lymphoma
- Lymphangioleiomyomatosis
- Mastocytosis
- Multiple Myeloma
- Myelodysplastic Syndrome
- Nausea and Vomiting – Chemotherapy Induced
- Neutropenia – Chemotherapy Induced
- Non-Small Cell Lung Cancer
- Ovarian Cancer
- Pain Relief in Cancer Patients
- Pancreatic Cancer
- Prostate Cancer
- Rectal Cancer
- Renal Cell Cancer
- Small Cell Lung Cancer
- Solid Tumors
- Subependymal Giant Cell Astrocytoma and Angiomyolipoma
- Thyroid Cancer
- Tumor Lysis Syndrome
- and others
EastHORN has experience in the following types of cancer treatments and palliative care:
- Angiogenesis inhibitors
- Antibodies
- Taxanes
- Platinum agents
- Antiemetics
- Alkylating agents
- Retinoids
- Radiosensitizers
- Antibodies
- Vaccines
- Interleukins
- Antiestrogens
- Growth factors